Data registry to capture real-world evidence of canaloplasty
Nova Eye Medical has established the iTrack Global Data Registry, which will collect prospective data on canaloplasty in the treatment of glaucoma, according to a press release.
The registry is a collaboration with the International Glaucoma Surgery Registry and will document real-world clinical evidence on the iTrack and iTrack Advance across North America, Europe and the Asia Pacific region.
“The iTrack Global Data Registry is providing high-quality, real-world evidence of the effectiveness and safety of canaloplasty to treat glaucoma and ocular hypertension,” Nathan Kerr, BHB, MBChB, MD, FRANZCO, said in the release. “Importantly, it provides a robust means by which to collect uniform data to evaluate specified outcomes across the spectrum of glaucoma. It will make a major contribution to our understanding of the clinical effectiveness of canaloplasty and will enable evidence-based decision-making.”
Ike K. Ahmed, MD, FRCSC, and David Lubeck, MD, will join Kerr in leading the registry.
Nova Eye Medical said the iTrack registry will follow canaloplasty outcomes for a minimum of 24 months and include more than 300 patients.